<p>勃艮第资产管理有限公司在最近向证券交易委员会提交的文件中表示，在第一季度将其在 Globas Medical, Inc.（纽约证券交易所代码：GMED - 免费报告）的持仓提高了 7.0%。该机构投资者在此期间额外购买了 183,639 股后，持有该医疗设备公司 2,801,747 股股票。Globas Medical 约占勃艮第资产管理有限公司持有资产的 2.1%，使其成为第八大持仓。勃艮第资产管理有限公司在最近的报告期末持有 Globas Medical 的股份占比为 2.04%，价值为 205,088,000 美元。</p>
<p>其他对冲基金也调整了对该公司的持仓。Farther Finance Advisors LLC 在第一季度将其在 Globas Medical 的持仓增加了 145.5%。Farther Finance Advisors LLC 现在持有 405 股该医疗设备公司的股票，价值 30,000 美元，此前在上个季度额外购买了 240 股。Larson Financial Group LLC 在第一季度将其在 Globas Medical 的持仓增加了 1,007.7%。Larson Financial Group LLC 现在持有 432 股该医疗设备公司的股票，价值 32,000 美元，此前在上个季度额外购买了 393 股。Parallel Advisors LLC 在第一季度将其在 Globas Medical 的持仓增加了 62.1%。Parallel Advisors LLC 现在持有 504 股该医疗设备公司的股票，价值 37,000 美元，此前在上个季度额外购买了 193 股。Versant Capital Management Inc 在第一季度将其在 Globas Medical 的持仓增加了 932.1%。Versant Capital Management Inc 现在持有 547 股该医疗设备公司的股票，价值 40,000 美元，此前在上个季度额外购买了 494 股。最后，Whittier Trust Co.在第一季度将其在 Globas Medical 的持仓增加了 46.5%。Whittier Trust Co.现在持有 580 股该医疗设备公司的股票，价值 42,000 美元，此前在上个季度额外购买了 184 股。95.16% 的股票由机构投资者和对冲基金持有。</p>
<p>获取 <strong>Globas Medical</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>GMED 已成为多份研究分析师报告的主题。Canaccord Genuity Group 在 7 月 22 日的研究报告中将 Globas Medical 的目标价从 97.00 美元下调至 90.00 美元，并对该股票给予 “买入” 评级。巴克莱在 6 月 10 日的研究报告中重申了对 Globas Medical 股票的 “增持” 评级。摩根士丹利在 7 月 15 日的研究报告中将 Globas Medical 的目标价从 75.00 美元下调至 68.00 美元，并对该公司给予 “增持” 评级。Truist Financial 在 5 月 12 日的研究报告中将 Globas Medical 的目标价从 80.00 美元下调至 68.00 美元，并对该公司给予 “持有” 评级。最后，Piper Sandler 在 5 月 9 日的研究报告中将 Globas Medical 的目标价从 100.00 美元下调至 80.00 美元，并对该公司给予 “增持” 评级。五位股票研究分析师对该股票给予 “持有” 评级，九位分析师对该公司给予 “买入” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 87.64 美元。</p>
<p><strong>获取我们关于 Globas Medical 的最新研究报告</strong></p>
<h2>Globas Medical 股价上涨 1.0%</h2>
<p>GMED 股票在周五开盘价为 60.63 美元。该公司的 50 日移动平均价格为 57.22 美元，200 日移动平均价格为 67.33 美元。该公司的市值为 82.1 亿美元，市盈率为 23.32，市盈增长比率为 1.68，贝塔值为 1.20。Globas Medical, Inc.的 1 年最低价为 51.79 美元，1 年最高价为 94.93 美元。</p>
<p>Globas Medical（纽约证券交易所代码：GMED - 获取免费报告）在 8 月 7 日发布了其财报。该医疗设备公司报告本季度每股收益为 0.86 美元，超出市场共识预期的 0.76 美元，超出 0.10 美元。该公司本季度的收入为 7.4534 亿美元，而分析师预期为 7.3891 亿美元。Globas Medical 的股本回报率为 10.65%，净利润率为 13.58%。该公司本季度的收入同比增长 18.4%。在去年同期，该公司每股收益为 0.75 美元。分析师平均预测 Globas Medical, Inc.在本年度的每股收益为 3.44 美元。</p>
<p>Globas Medical 宣布其董事会于 5 月 15 日启动了一项股票回购计划，允许公司回购 5 亿美元的流通股。该回购授权允许该医疗设备公司通过公开市场购买最多 6.3% 的股份。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
<h2>Globas Medical 公司简介</h2>
<p>（免费报告）</p>
<p>Globas Medical, Inc.是一家医疗设备公司，开发和商业化针对美国及国际上肌肉骨骼疾病患者的医疗解决方案。该公司提供脊柱产品，如传统融合植入物，包括椎弓根螺钉和杆系统、板系统、椎间隔器和用于治疗退行性和先天性疾病、畸形、肿瘤和创伤性损伤的椎体切除装置；运动保留技术的治疗选择，包括动态稳定、全椎间盘置换和椎间分离装置；治疗椎体压缩骨折的介入解决方案；以及包括同种异体移植物和合成替代品的再生生物产品。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 Globas Medical 更好</li>
<li>何时出售股票以获利或亏损</li>
<li>3 只能源股以获得碳捕集热潮的曝光</li>
<li>10 美元以下的最佳股票</li>
<li>AI 眼镜会取代智能手机吗？Meta 正瞄准苹果</li>
<li>如何计算期权利润</li>
<li>福特股票上涨的真正原因——它能持续吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何关于此故事的问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Globus Medical 吗？</h2>
<p>在考虑 Globus Medical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Globus Medical 并不在名单上。</p>
<p>虽然 Globus Medical 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Globus医疗

<p>Burgundy Asset Management Ltd. 在第一季度将其在 Globus Medical, Inc. (NYSE:GMED) 的持股增加了 7.0%，目前拥有 2,801,747 股。该股票占 Burgundy 持有资产的 2.1%，价值 2.05 亿美元。其他对冲基金也显著增加了他们的持仓。分析师的评级意见不一，普遍共识为 “适度买入”，平均目标价格为 87.64 美元。Globus Medical 报告了强劲的收益，超出预期，并宣布了一项 5 亿美元的股票回购计划</p>

<p>Burgundy Asset Management Ltd. raised its position in Globus Medical, Inc. (NYSE:GMED - Free Report) by 7.0% in the 1st quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor owned 2,801,747 shares of the medical device company's stock after acquiring an additional 183,639 shares during the period. Globus Medical comprises approximately 2.1% of Burgundy Asset Management Ltd.'s holdings, making the stock its 8th largest holding. Burgundy Asset Management Ltd. owned 2.04% of Globus Medical worth $205,088,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>勃艮第资产管理有限公司在最近向证券交易委员会提交的文件中表示，在第一季度将其在 Globas Medical, Inc.（纽约证券交易所代码：GMED - 免费报告）的持仓提高了 7.0%。该机构投资者在此期间额外购买了 183,639 股后，持有该医疗设备公司 2,801,747 股股票。Globas Medical 约占勃艮第资产管理有限公司持有资产的 2.1%，使其成为第八大持仓。勃艮第资产管理有限公司在最近的报告期末持有 Globas Medical 的股份占比为 2.04%，价值为 205,088,000 美元。</p>
</div><p>Other hedge funds have also modified their holdings of the company. Farther Finance Advisors LLC grew its position in Globus Medical by 145.5% during the 1st quarter. Farther Finance Advisors LLC now owns 405 shares of the medical device company's stock worth $30,000 after acquiring an additional 240 shares during the last quarter. Larson Financial Group LLC grew its position in Globus Medical by 1,007.7% during the 1st quarter. Larson Financial Group LLC now owns 432 shares of the medical device company's stock worth $32,000 after acquiring an additional 393 shares during the last quarter. Parallel Advisors LLC grew its position in Globus Medical by 62.1% during the 1st quarter. Parallel Advisors LLC now owns 504 shares of the medical device company's stock worth $37,000 after acquiring an additional 193 shares during the last quarter. Versant Capital Management Inc grew its position in Globus Medical by 932.1% during the 1st quarter. Versant Capital Management Inc now owns 547 shares of the medical device company's stock worth $40,000 after acquiring an additional 494 shares during the last quarter. Finally, Whittier Trust Co. grew its position in Globus Medical by 46.5% during the 1st quarter. Whittier Trust Co. now owns 580 shares of the medical device company's stock worth $42,000 after acquiring an additional 184 shares during the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他对冲基金也调整了对该公司的持仓。Farther Finance Advisors LLC 在第一季度将其在 Globas Medical 的持仓增加了 145.5%。Farther Finance Advisors LLC 现在持有 405 股该医疗设备公司的股票，价值 30,000 美元，此前在上个季度额外购买了 240 股。Larson Financial Group LLC 在第一季度将其在 Globas Medical 的持仓增加了 1,007.7%。Larson Financial Group LLC 现在持有 432 股该医疗设备公司的股票，价值 32,000 美元，此前在上个季度额外购买了 393 股。Parallel Advisors LLC 在第一季度将其在 Globas Medical 的持仓增加了 62.1%。Parallel Advisors LLC 现在持有 504 股该医疗设备公司的股票，价值 37,000 美元，此前在上个季度额外购买了 193 股。Versant Capital Management Inc 在第一季度将其在 Globas Medical 的持仓增加了 932.1%。Versant Capital Management Inc 现在持有 547 股该医疗设备公司的股票，价值 40,000 美元，此前在上个季度额外购买了 494 股。最后，Whittier Trust Co.在第一季度将其在 Globas Medical 的持仓增加了 46.5%。Whittier Trust Co.现在持有 580 股该医疗设备公司的股票，价值 42,000 美元，此前在上个季度额外购买了 184 股。95.16% 的股票由机构投资者和对冲基金持有。</p>
</div><p>Get <strong>Globus Medical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Globas Medical</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>GMED has been the topic of a number of research analyst reports. Canaccord Genuity Group decreased their price target on Globus Medical from $97.00 to $90.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, July 22nd. Barclays reissued an &#34;overweight&#34; rating on shares of Globus Medical in a research note on Tuesday, June 10th. Morgan Stanley lowered their target price on Globus Medical from $75.00 to $68.00 and set an &#34;overweight&#34; rating for the company in a research note on Tuesday, July 15th. Truist Financial lowered their target price on Globus Medical from $80.00 to $68.00 and set a &#34;hold&#34; rating for the company in a research note on Monday, May 12th. Finally, Piper Sandler lowered their target price on Globus Medical from $100.00 to $80.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday, May 9th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $87.64.</p>
<div class="lb-trans"><p>GMED 已成为多份研究分析师报告的主题。Canaccord Genuity Group 在 7 月 22 日的研究报告中将 Globas Medical 的目标价从 97.00 美元下调至 90.00 美元，并对该股票给予 “买入” 评级。巴克莱在 6 月 10 日的研究报告中重申了对 Globas Medical 股票的 “增持” 评级。摩根士丹利在 7 月 15 日的研究报告中将 Globas Medical 的目标价从 75.00 美元下调至 68.00 美元，并对该公司给予 “增持” 评级。Truist Financial 在 5 月 12 日的研究报告中将 Globas Medical 的目标价从 80.00 美元下调至 68.00 美元，并对该公司给予 “持有” 评级。最后，Piper Sandler 在 5 月 9 日的研究报告中将 Globas Medical 的目标价从 100.00 美元下调至 80.00 美元，并对该公司给予 “增持” 评级。五位股票研究分析师对该股票给予 “持有” 评级，九位分析师对该公司给予 “买入” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 87.64 美元。</p>
</div><p><strong>Get Our Latest Research Report on Globus Medical</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Globas Medical 的最新研究报告</strong></p>
</div><h2>Globus Medical Trading Up 1.0%</h2>
<div class="lb-trans"><h2>Globas Medical 股价上涨 1.0%</h2>
</div><p>GMED stock opened at $60.63 on Friday. The business's 50-day moving average price is $57.22 and its two-hundred day moving average price is $67.33. The firm has a market cap of $8.21 billion, a PE ratio of 23.32, a P/E/G ratio of 1.68 and a beta of 1.20. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $94.93.</p>
<div class="lb-trans"><p>GMED 股票在周五开盘价为 60.63 美元。该公司的 50 日移动平均价格为 57.22 美元，200 日移动平均价格为 67.33 美元。该公司的市值为 82.1 亿美元，市盈率为 23.32，市盈增长比率为 1.68，贝塔值为 1.20。Globas Medical, Inc.的 1 年最低价为 51.79 美元，1 年最高价为 94.93 美元。</p>
</div><p>Globus Medical (NYSE:GMED - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical device company reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.76 by $0.10. The firm had revenue of $745.34 million for the quarter, compared to analyst estimates of $738.91 million. Globus Medical had a return on equity of 10.65% and a net margin of 13.58%. The company's revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 earnings per share. On average, analysts forecast that Globus Medical, Inc. will post 3.44 earnings per share for the current year.</p>
<div class="lb-trans"><p>Globas Medical（纽约证券交易所代码：GMED - 获取免费报告）在 8 月 7 日发布了其财报。该医疗设备公司报告本季度每股收益为 0.86 美元，超出市场共识预期的 0.76 美元，超出 0.10 美元。该公司本季度的收入为 7.4534 亿美元，而分析师预期为 7.3891 亿美元。Globas Medical 的股本回报率为 10.65%，净利润率为 13.58%。该公司本季度的收入同比增长 18.4%。在去年同期，该公司每股收益为 0.75 美元。分析师平均预测 Globas Medical, Inc.在本年度的每股收益为 3.44 美元。</p>
</div><p>Globus Medical announced that its board has initiated a stock buyback plan on Thursday, May 15th that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the medical device company to reacquire up to 6.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.</p>
<div class="lb-trans"><p>Globas Medical 宣布其董事会于 5 月 15 日启动了一项股票回购计划，允许公司回购 5 亿美元的流通股。该回购授权允许该医疗设备公司通过公开市场购买最多 6.3% 的股份。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
</div><h2>Globus Medical Profile</h2>
<div class="lb-trans"><h2>Globas Medical 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.</p>
<div class="lb-trans"><p>Globas Medical, Inc.是一家医疗设备公司，开发和商业化针对美国及国际上肌肉骨骼疾病患者的医疗解决方案。该公司提供脊柱产品，如传统融合植入物，包括椎弓根螺钉和杆系统、板系统、椎间隔器和用于治疗退行性和先天性疾病、畸形、肿瘤和创伤性损伤的椎体切除装置；运动保留技术的治疗选择，包括动态稳定、全椎间盘置换和椎间分离装置；治疗椎体压缩骨折的介入解决方案；以及包括同种异体移植物和合成替代品的再生生物产品。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Globus Medical</li>
<li>When to Sell a Stock for Profit or Loss</li>
<li>3 Energy Stocks to Gain Exposure to the Carbon Capture Boom</li>
<li>Best Stocks Under $10.00</li>
<li>AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple</li>
<li>How to Calculate Options Profits</li>
<li>The Real Reason Ford Stock Is Rallying—Can It Keep Going?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Globas Medical 更好</li>
<li>何时出售股票以获利或亏损</li>
<li>3 只能源股以获得碳捕集热潮的曝光</li>
<li>10 美元以下的最佳股票</li>
<li>AI 眼镜会取代智能手机吗？Meta 正瞄准苹果</li>
<li>如何计算期权利润</li>
<li>福特股票上涨的真正原因——它能持续吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=GMED"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何关于此故事的问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Globus Medical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Globus Medical 吗？</h2>
</div><p>Before you consider Globus Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Globus Medical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Globus Medical 并不在名单上。</p>
</div><p>While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Globus Medical 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Burgundy Asset Management Ltd. 购入了 Globus Medical Inc. (NYSE:GMED) 的股份